Time：2025-11-11
Medtide Inc. ("the Company"; Stock Code: 3880) has been officially named a 2025 "Hangzhou Headquarters Enterprise", in recognition of its leading comprehensive strength in peptides and oligonucleotides. The honor underscores the company’s pivotal role in headquarters economy and its benchmark status in the global peptide and oligonucleotide drug R&D, production and service sector.
About Medtide Inc.
Medtide Inc. is apeptide-focused contract research, development, and manufacturing organization(CRDMO), offering full-cycle services ranging from early-stage discovery,pre-clinical research and clinical development to commercial-stage production.The company is headquartered in Hangzhou, China, and has commercial productionbases and offices in both China and the United States. We have been deeplyinvolved in the peptide field for over 20 years. Today, we have become a CRDMOwith global operations and comprehensive service capabilities.
Medtide Inc. provides (i)contract research organization (CRO) services,namely peptide new chemicalentity (NCE) discovery synthesis; and (ii) contract development andmanufacturing organization (CDMO) services,namely peptide chemistry,manufacturing and controls (CMC) development and commercial manufacturing. Wehave established global operations, with projects covering over 50 countries,including major markets such as China, the United States, Japan, Europe, SouthKorea, and Australia. We provide our 1000+ customers with peptide drugdevelopment, production, and CMC documentation and filing support services thatmeet regulatory requirements in major markets worldwide.
As a trusted and sustainable enterprise, Medtide Inc. hasestablished long-term partnerships with many customers. Through closecollaboration, we assist customers in bringing drugs that profoundly impacthuman health to the market, focusing on patients and committed to improvingtheir lives, thus promoting the development of the human health industry.
